Pathophysiology as a basis for understanding symptom complexes and therapeutic targets
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Abstract Sensorimotor disorders of the stomach, small intestine and colon have a limited repertoire of clinical manifestations, and there is the potential for more than one mechanism to lead to symptoms. In many recent clinical trial programs of novel agents in neurogastroenterology, the emphasis has been primarily on symptom assessment of broad groups of patients identified by the Rome criteria. Drugs of potential value have fallen by the wayside with this approach. We propose the current paradigm is partly to blame; physiological testing should provide the basis for identifying more homogeneous populations and therapeutic targets within functional bowel disease, and this applies to the upper and lower gut. Here we summarize the evidence that certain biomarkers can, in a limited fashion, be used to predict the success of an experimental medicine in common disorders of gastrointestinal function, including the irritable bowel syndrome and functional dyspepsia. Although the current evidence is limited and is most convincingly demonstrated with examples of transit measurements (for loperamide, alosetron, tegaserod and piboserod), we perceive this paradigm that studies using validated and responsive biomarkers have an important role to play in drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Prather, C. M., Camilleri, M., Zinsmeister, A. R., McKinzie, S., & Thomforde, G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70251-4 · Cited by 410
Self-citationGastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms
Bredenoord, A. J., Chial, H. J., Camilleri, M., Mullan, B. P., & Murray, J. A. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00130-7 · Cited by 243
Self-citationEfficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
Cremonini, F., Delgado‐Aros, S., & Camilleri, M. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00389.x · Cited by 219
Self-citationAlosetron Improves Quality of Life in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Watson, M. E., Lacey, L., Kong, S., Northcutt, A. R., McSorley, D., Hahn, B., & Mangel, A. W. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03525.x · Cited by 88
Cited by
Gershon, M. D. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02180.x · Cited by 521
Guidelines for the Management of Dyspepsia
Talley, N. J., Vakil, N., & the Practice Parameters Committee of the American College of Gastroenterology (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00225.x · Cited by 489
Self-citationAmerican Gastroenterological Association Technical Review on the Evaluation of Dyspepsia
Talley, N. J., Vakil, N. B., & Moayyedi, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.020 · Cited by 440
Self-citationFundamentals of Neurogastroenterology: Basic Science
Vanner, S. J., Greenwood-Van Meerveld, B., Mawe, G. M., Shea-Donohue, T., Verdu, E. F., Wood, J., & Grundy, D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.018 · Cited by 369
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285
Metadata
- Authors
- Camilleri, M., & Talley, N. J.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2004-04
- Volume
- 16
- Issue
- 2
- Pages
- 135-142
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W2063911370
- Cited by
- 80
- References
- 7
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.